The O’Neill Institute is working in partnership with NMAC to examine the status of biomedical HIV prevention research and implementation in the United States. The focus of the project is to explore how to bring the promise of biomedical HIV prevention to all communities highly impacted by HIV. Biomedical HIV prevention offers a range of tools that can effectively prevent HIV infection. These tools include treatment as prevention (TasP), pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP).
The O’Neill Institute will produce a two-part report, Blueprint for HIV Biomedical Prevention. The first of two reports, “Blueprint for HIV Biomedical Prevention: State of the State,” was released on December 3, 2016 at the National HIV PrEP Summit in San Francisco. The State of the State report provides an overview of policies and programs that are critical to effective biomedical HIV prevention in communities of color. The report highlights current health department and community efforts to implement the new science. It also includes descriptions of the roles played by selected federal agencies in supporting biomedical HIV prevention and identifies some of their key recent initiatives.
The second of two reports, “Expanding Access to Biomedical HIV Prevention: Tailoring Approaches for Effectively Serving Communities of Color,” was released on April 10, 2018 and shares policy recommendations on ways to expand access to PrEP and TasP/treatment as prevention. This report highlights the unique challenges people of color face in HIV prevention, care, and treatment and gives ways to improve outreach to gay men of color, women of color, and the transgender community.